150 17 Text (including references): 8127 18 Text (excluding references): 5173 19 20 Practice Points 21 • Clinical events during the natural history of chronic hepatitis B virus (HBV) are 22 Abstract 36 Clinical events and the host immune response during hepatitis B virus (HBV) infection are 37 intricately linked. Despite decades of research, important questions concerning the 38 immunopathogenesis of chronic HBV infection remain unanswered. For example, it is 39 unclear which immune parameters facilitate persistence, and if HBV can be completely 40 cleared from the human liver. Recent technological breakthroughs now allow researchers to 41 address these seemingly basic, but essential questions surrounding HBV immunity. It will be 42 important to better define the molecular underpinnings of immune cell function and 43 dysfunction during chronic disease and in controlled infection, with particular focus on the 44 liver, as little information is available on the intrahepatic compartment. In the near future, it 45 may be possible to solve some of the controversy surrounding the immune responses to 46 HBV, and establish the features of both the innate and adaptive arms of the immune system 47 required to achieve sustained control of HBV infection. 48 M
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intricately linked to the host immune system, but the details of host-virus interactions 23 remain insufficiently understood 24
• HBV is sensed by the immune system, but the ensuing antiviral responses are not 25 sufficient to prevent chronicity in most newborns and some adults 26 27 Research Agenda 28
• To understand the basic mechanisms of HBV clearance, persistence and long lasting 29 HBV cure by using the most advanced and detailed biomedical techniques, down to 30 the single cell level. 31
• To gather more information on the intrahepatic, rather than the peripheral, immune 32 populations, as their phenotype and function are very different 33
• To focus on longitudinal assessment of immune parameters, thereby excluding 34 effects of cohort variation in HBV research M A N U S C R I P T
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and analytical capabilities now allow researchers to address seemingly basic but still 55 unsolved questions surrounding HBV immunity. We have formulated several questions 56 regarding host-virus interactions whose answers we deem most relevant for a better 57 understanding of HBV immunopathogenesis and for the development of novel therapeutic 58 strategies (Figure 1 ). After addressing these issues, we will highlight some of the progress 59 that has already been made in the field of chronic HBV. 60
First is the question of what determines the different outcome in acute HBV infection, 61
as the virus is spontaneously controlled in some subjects, while becoming chronic in others. 62
Here we have to consider two completely distinct scenarios: adult HBV infection typically 63 leads to HBV control, whereas natal infection results in chronicity in almost all cases, with 64 declining but still very significant chronicity rates if infection occurs before the age of 5. 65
However, not much is known of the immunological processes, resulting in these striking 66 differences. We know much more about acute and chronic infection "after the fact", i.e. in 67 adult patients who have established chronic infection or successful HBV control. Studies 68 during the early phase of infection, when the outcome is not yet determined, are much more 69 difficult to undertake. The best opportunity for further insights will be studies in young 70 children who present with early infection. Immunological studies in this population are 71 feasible, but until recently had to be very limited in scope, in part because only small 72 amounts of blood can be drawn for analysis. New technologies now enable analysis of low 73 volume samples with high resolution and without the requirement of research facilities close 74 to the clinic. 75
Immune responses of chronically infected adults have been performed for decades, 76 but, as we will describe in this review, often have conflicting results. These variations are 77 partly caused by methodological differences, but the variation among patient characteristics 78 also has significant impact [1] . In addition to establishing the range and variation of immune 79 cell parameters during frequent subtypes of chronic infection, we also need to know if, and to 80 what degree, antiviral therapy is able to reconstitute those parts of the HBV immune 81 response previously insufficient for functional control. At least based on the different antibody 82 patterns observed in treated patients, it seems obvious that restoration of immunity is not 83 uniform, and certainly in most subjects not sufficient for viral control in the absence of
therapy. But what exactly is restored, whether immune restoration is just a consequence of 85 diminished viral replication that is lost in the absence of antiviral treatment, or whether 86 restored immunity is independent or even the cause of viral suppression, needs to be 87 evaluated in much more detail. In this context it is also important to define whether circulating 88 viral proteins, such as HBs antigen (HBsAg), are indeed the key immunosuppressive agents 89 that in vitro studies have suggested [2] . 90
Another important question is what level of HBV control can actually be achieved 91 through the host immune response. It is clear that even after HBsAg clearance from the 92 blood, covalently closed circular DNA (cccDNA) can remain in hepatocytes indeterminately, 93 evident from the well-documented cases of HBV reactivation in anti-HBsAg positive subjects 94 undergoing immune-ablative therapies. Whether this is the dominant or even the only 95 scenario in "resolved" HBV infection, or whether some patients are indeed able to completely 96 clear HBV DNA based on an even more effective immune response, will require larger 97 studies analyzing liver tissue for cccDNA in these populations. 98
Finally, greater insights need to be generated into what actually happens in the liver 99 as the site of infection, since both the composition of immune populations as well as their 100 functional and phenotypic profiles are different from what is observed in the blood. New 101 technologies now allow analysis of rare immune populations in the liver, down to cells on the 102 single cell level. Similarly, we should utilize the improved tools for the integrative analysis of 103 cellular processes and immune functions in order to understand the immune response to 104 HBV more holistically. Many components of the immune response, both innate and adaptive, 105 have to act in concert in different scenarios of viral control and viral persistence. Below we 106
will broadly summarize the current knowledge of both innate and adaptive arms of the 107 immune responses to HBV infection. While the studies described below do not yet provide 108 definitive answers, they are the foundation for future investigations into the issues raised 109
Innate immune responses to HBV
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HBV is transmitted upon contact with blood or body fluids of an infected person. A minute 114 amount of HBV virions in the bloodstream is sufficient for infection of hepatocytes [3] . The 115 HBV virion enters the hepatocyte via the sodium taurocholate co-transporting polypeptide 116 (NTCP), a bile receptor located on the basolateral membrane, contributing to its specificity to 117 human or chimpanzee hepatocytes [4] . After the envelope protein mediates fusion of the viral 118 and endosomal membranes, the capsid enters the cytoplasm and the viral DNA is released 119 into the nucleus through nuclear pores. Upon import into the nucleus, HBV can integrate into 120 the host genome or be present as non-integrated covalently closed circular DNA (cccDNA). 121
The cccDNA molecule will serve as a template for replication leading to infection of more 122 hepatocytes, and can persist even after HBsAg loss [5] . As circulating blood passes the liver, 123
HBV can easily spread to other hepatocytes. As the human liver is the site of HBV replication and contains high viral protein 148 concentrations, the most appropriate approach for addressing basic questions concerning 149 HBV detection is to evaluate liver material. Unfortunately, such studies are rare. Lebosse et 150 al.
[11] analyzed RNA extracted from liver biopsies of chronic HBV patients and showed low 151 intrahepatic IFNɑ expression relative to healthy controls, which was unaffected by viral 152 replication. Previously, we analyzed liver biopsies from patients in specific clinical phases of 153 chronic HBV. By comparing the transcriptome of liver and blood samples from patients in 154 distinct clinical phases of HBV we found that, ISG are transcribed even in patients presumed 155 to be 'immune tolerant' to HBV [12] . Transcription of catalytic polypeptide-like 3B, a protein 156 related to cccDNA degradation [13] , was increased in the immune tolerant phase, which 157 suggests that the capacity to limit the establishment of high amounts of cccDNA may be 158 different between phases, but not absent in any phase. These two studies using human liver 159 tissue raise significant doubt about the labels 'stealth virus' and 'immune tolerant', as HBV is 160 indeed sensed by the host immune system and antiviral responses are initiated, even as they 161
are not sufficient to halt viral replication and spread in persons with chronic infection. 162
Whether these differences of innate intrahepatic responses are caused by chronic HBV 163 replication, or reflect immune characteristics that select patients for persistent infection, 164 remains to be clarified using longitudinally acquired samples of human liver. 165 166
The interaction of antigen presenting cells and HBV 167
Intrahepatic leukocyte populations lining the sinusoidal lumen of the portal branches as well 168 as hepatocytes are constantly in contact with huge amounts of bacterial antigen derived from 169 the gut. Tolerance during exposure to high antigen loads is essential for host survival, and 170 the relative tolerogenic milieu of the liver is well described [14] . Illustrative of the complex 171 balance of the liver immune system is the fact that, despite its tolerant nature, HBV is cleared 172 after transmission in the vast majority of infected individuals. For the development of 173 treatment strategies, it is important to evaluate the leukocyte populations involved in this 174
process. Liver residing antigen presenting cells, like Kupffer cells and dendritic cells (DC), 175
could potentially modulate host immune responses to a phenotype enabling chronic viral 176 infection, but limited information exists on the interaction between these cells and HBV 177 intrahepatic leukocytes [21] . We have previously shown that Kupffer cells can interact with 193
HBsAg in vivo, which led to increased pro-inflammatory cytokine production compared to only a subset of human chronic HBV patients, and the treatment was not well tolerated [35] . 223
During chronic HBV infection, the cytotoxic capacity of NK cells seems to remain intact [36] , 224 which together with the impaired cytokine production as described by some studies, 225
suggests the existence of a functional dichotomy of NK cells in chronic HBV. However, given 226 the conflicting reports in the literature, it is obvious that more detailed and more controlled 227 studies need to be performed. 
Detection of HBV-specific CD8 T cells 299
In contrast to CD4 T cells, CD8 T cell responses have been studied much more widely and in 300 greater detail, including direct ex vivo analyses [56] . They are essential for HBV control, as 301 their depletion invariantly led to chronicity in chimpanzees [46] . HBV-specific CD8 T cells 302 become readily detectable six to eight weeks after infection in adults, and their appearance 303 coincides with a decrease in viral load that is observed even before the onset of liver Once patients are chronically infected, especially in those patients exposed in early 335 childhood, there is usually an extended phase that has been described as immune tolerant, 336 with high levels of viremia but no or very little liver disease. It has been postulated that during 
